Skip to main content

Table 1 MPTP mouse model groups

From: The potassium channel KCa3.1 represents a valid pharmacological target for microgliosis-induced neuronal impairment in a mouse model of Parkinson’s disease

Groups (n = 10–15/group)Treatment (day1–5)
MPTP20 mg/kg, once daily, i.p. day1–5
MPTP+senicapocMPTP (20 mg/kg, once daily, i.p. day1–5) + senicapoc (100 mg/kg, once daily, p.o. day1–5, 1 h prior to MPTP exposure)
Senicapoc100 mg/kg, once daily, p.o. day1–5
WT+MPTP20 mg/kg, once daily, i.p. day1–5
KCa3.1−/−+MPTP20 mg/kg, once daily, i.p. day1–5